Loading...
Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!
- Ticker
- MVIR.ST
- Price
- 1.61
- Stock movement down
- -0.10 (-5.03%)
- Company name
- Medivir AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Markkapitalisasie
- 207.74M
- Ondernemingswaarde
- -
- Prys/Verkope
- -
- Prys/Boek
- -
- Dividendopbrengs
- -
- Dividendgroei
- -
- Groei jare
- -
- FCF uitbetaling
- -
- Agterlopende P/E
- -
- Volgende P/E
- -
- PEG
- -
- EPS groei
- -
- 1 jaar opbrengs
- -38.68%
- 3 jaar opbrengs
- -38.00%
- 5 jaar opbrengs
- -31.30%
- 10 jaar opbrengs
- -30.66%
Laaste opgedateer: 2025-09-17
DIVIDENDE
MVIR.ST betaal nie dividende nie of geen data is ontvang nie
WAARDERING
Waarderingsverhoudings
Loading...
Waarderingsverhoudings gegewens
| Agterlopende P/E | - |
| Prys tot OCF | - |
| Prys tot FCF | - |
| Prys tot EBITDA | - |
| EV tot EBITDA | - |
Waardering (Verkope/Boekwaarde)
Loading...
Waardering (Verkope/Boekwaarde) gegewens
| Prys tot verkope | - |
| Prys tot Boekwaarde | - |
| EV tot verkope | - |
FINANSIËLE
AANDELE INLIGTING
Aandele grafiek
Loading...
Aandele prys data
| Open | 1.97 |
| Daaglikse hoog | 2.00 |
| Daaglikse laag | 1.85 |
| Daaglikse volume | 182K |
| Hoogtepunt van alle tye | 190.06 |
| 1j analiseraaming | 20.71 |
| Beta | -0.23 |
| EPS (TTM) | - |
| Dividend per aandeel | - |
| Ex-dividend datum | - |
| Volgende verdienste datum | 6 Nov 2025 |
Afwaartse potensiaal
Loading...
Afwaartse potensiaal gegewens
| MVIR.ST | S&P500 | |
| Huidige prysdaling vanaf die hoogste punt van alle tye | -99.03% | -1.06% |
| Hoogste prysdaling | -99.35% | -56.47% |
| Datum van hoogste daling | 7 Apr 2025 | 9 Mar 2009 |
| Gemiddelde daling vanaf hoogtepunt | -75.66% | -10.99% |
| Gemiddelde tyd tot nuwe hoogtepunt | 407 days | 12 days |
| Maksimum tyd tot nuwe hoogtepunt | 6471 days | 1805 days |
MAATSKAPPY BESONDERHEDE
Markkapitalisasie
207.74M
Markkapitalisasie kategorie
Small-cap
Beskrywing
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Werknemers
10
Webwerf
Beleggerverhoudings
-
SEC lêers
CEO
Land
Sweden
Stad
Aandele tipe
-
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Alle nuusPersvrystellings
Medivir AB (STU:MVR0) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (STU:MVR0) reports promising clinical developments and patent extensions, while navigating funding hurdles to sustain its innovative pipeline.
22 Augustus 2025
STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin...
20 Augustus 2025
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining flat over a four-day period, while major indexes such as France's CAC 40 and Italy's FT...
9 Julie 2025
As European markets continue to navigate a landscape marked by mixed performances and hopes for easing trade tensions, investors are increasingly seeking opportunities in less conventional areas. Penn...
15 Mei 2025
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks rema...
16 April 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently saw a slight decline. Despite these challenges, ...
18 Maart 2025
Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (FRA:MVR0) reports significant progress in liver cancer treatment development, despite facing increased clinical costs and market competition.
19 Februarie 2025
Global markets have recently experienced mixed performances, with major stock indexes showing a combination of gains and declines as the year closed out. For investors looking beyond traditional blue-...
6 Januarie 2025